Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human Arboviral Infections in Italy: Past, Current, and Future Challenges.
Rossi B, Barreca F, Benvenuto D, Braccialarghe N, Campogiani L, Lodi A, Aguglia C, Cavasio RA, Giacalone ML, Kontogiannis D, Moccione M, Malagnino V, Andreoni M, Sarmati L, Iannetta M. Rossi B, et al. Among authors: barreca f. Viruses. 2023 Jan 27;15(2):368. doi: 10.3390/v15020368. Viruses. 2023. PMID: 36851582 Free PMC article. Review.
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients.
Di Lorenzo A, Tedde S, Pace PG, Campogiani L, Ansaldo L, Lodi A, Zordan M, Barreca F, Caldara F, Rossi B, Imeneo A, Alessio G, Crea AMA, Checchi D, Malagnino V, Teti E, Coppola L, Palmieri R, Buccisano F, Andreoni M, Sarmati L, Iannetta M. Di Lorenzo A, et al. Among authors: barreca f. Biomedicines. 2022 Nov 2;10(11):2788. doi: 10.3390/biomedicines10112788. Biomedicines. 2022. PMID: 36359306 Free PMC article.
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity.
Pannek M, Alhalabi Z, Tomaselli D, Menna M, Fiorentino F, Robaa D, Weyand M, Puhlmann M, Tomassi S, Barreca F, Tafani M, Zaganjor E, Haigis MC, Sippl W, Rotili D, Mai A, Steegborn C. Pannek M, et al. Among authors: barreca f. J Med Chem. 2024 Feb 8;67(3):1843-1860. doi: 10.1021/acs.jmedchem.3c01496. Epub 2024 Jan 22. J Med Chem. 2024. PMID: 38253001
Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity and Downregulate Hypoxia-Induced Targets in Cancer Cells.
Zwergel C, Aventaggiato M, Garbo S, Di Bello E, Fassari B, Noce B, Castiello C, Lambona C, Barreca F, Rotili D, Fioravanti R, Schmalz T, Weyand M, Niedermeier A, Tripodi M, Colotti G, Steegborn C, Battistelli C, Tafani M, Valente S, Mai A. Zwergel C, et al. Among authors: barreca f. J Med Chem. 2023 Jul 27;66(14):9622-9641. doi: 10.1021/acs.jmedchem.3c00337. Epub 2023 Jul 13. J Med Chem. 2023. PMID: 37439550 Free PMC article.
32 results